Skip to main content

Investors impressed by WTC’s results | WiseTech Global (ASX:WTC)

Grady Wulff
August 24, 2022

Logistics software solution provider WiseTech Global (ASX:WTC) released its FY22 results today that have impressed investors and well exceeded market expectations.

Underlying NPAT soared 72% to $181.8 million on the back of price increases in H2 of the financial year, total revenue rose 26% to $632.2 million, EBITDA increased 54%, net cost reductions of $32.6 million, and the company announced a final dividend of 6.4 cents per share, an increase of 66% on FY21.

In a year where global supply chains were heavily disrupted, WiseTech Global thrived through its CargoWise global software platform for international logistics service providers, including the signing of five new rollouts of CargoWise signed in FY22.

On the expansion front, WiseTech Global completed two takeovers in FY22, acquiring Inobiz and Hazmatica.

The logistics software provider also provided FY23 guidance including EBITDA between the range of $385 million -$415 million and revenue growth between 20%-23%.

Looking at broker ratings since the results were released, Citi has maintained its neutral rating and price target of $51 per share on WiseTech Global after the company reported cash conversion declined in FY22.

However, investors are piling into WiseTech Global shares today, driving the share price up 10.75% today so far.

Morning Bell 29 March

Paulina Peters
March 29, 2022

Morning Bell 28 March

Sophia Mavridis
March 28, 2022

Weekly Wrap 25 March

Sophia Mavridis
March 25, 2022

Morning Bell 24 March

Sophia Mavridis
March 24, 2022

Morning Bell 23 March

Paulina Peters
March 23, 2022

Morning Bell 22 March

Paulina Peters
March 22, 2022

Morning Bell 21 March

Sophia Mavridis
March 21, 2022

Weekly Wrap 18 March

Sophia Mavridis
March 18, 2022

Morning Bell 17 March

Paulina Peters
March 17, 2022

Morning Bell 16 March

Sophia Mavridis
March 16, 2022

Morning Bell 15 March

Paulina Peters
March 15, 2022

Morning Bell 14 March

Sophia Mavridis
March 14, 2022